(Hypertension. 1995;25:186-193.)
© 1995 American Heart Association, Inc.
Articles |
Role of Nitric Oxide in the Regulation of Coronary Vascular Tone in Hearts From Hypertensive Rats
Maintenance of Nitric Oxide–Forming Capacity and Increased Basal Production of Nitric Oxide
From the Department of Medicine, Division of Cardiology (M.K., T.K., W.M, B.E.S.), and Department of Physiology (A.D.), Heinrich-Heine Universität Düsseldorf, and the Department of Pharmacology, Schwarz Pharma AG Monheim (M.F.) (Germany).
Correspondence to Dr Malte Kelm, Department of Medicine, Division of Cardiology, Pneumology and Angiology, Heinrich-Heine-Universität, Moorenstraße 5, 40225 Düsseldorf, FRG.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract In arterial hypertension, coronary flow reserve, expressed by the difference between autoregulated and maximal coronary flow, is frequently impaired. Previous experimental and clinical investigations using acetylcholine as a stimulus for the production of endothelium-derived relaxing factor suggested that an impaired endothelium-dependent vasodilation, presumably caused by a decreased formation of nitric oxide (NO), may account for this microvascular dysfunction. However, so far no study has been performed that quantifies the formation of NO within the coronary circulation of hypertensive hearts to assess its role in setting coronary vascular tone in the hypertensive heart. We therefore quantified NO formation within the coronary circulation of constant flow–perfused, isolated hearts from spontaneously hypertensive rats (SHR, 16th to 26th week), as a model for hypertensive heart disease, and from the normotensive control strain (Wistar-Kyoto, WKY) using the oxyhemoglobin technique. Coronary perfusion pressure and vascular resistance were almost 30% higher in SHR compared with WKY hearts. Intracoronarily applied NO decreased coronary vascular resistance by maximally 45% of resting values in a concentration-dependent manner in both groups. The bradykinin-induced decrease in coronary vascular resistance and the parallel increase in NO release were comparable in SHR and WKY hearts and fell within the vasodilator range of exogenously applied NO. Moreover, basal release of NO normalized to heart wet weight was 50% higher in SHR compared with WKY hearts. Rates of basal NO release were correlated inversely with changes in coronary perfusion pressure and vascular resistance in both groups (r=-.85 and -.84, respectively, P<.05). This relation between resting coronary vascular resistance and NO formation, as a critical determinant of coronary flow, was shifted significantly to higher levels in SHR. From the present data we conclude that in the coronary circulation of SHR, NO formation is preserved under basal and stimulated conditions and critically determines resting coronary resistance. Moreover, the enhanced basal release of NO may serve the purpose of compensating the higher coronary vascular resistance of hypertensive hearts.
Key Words: endothelium-derived relaxing factor • nitric oxide • hypertension, arterial • coronary circulation • bradykinin
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The endothelium contributes to the control of vascular smooth muscle tone by production and release of nitric oxide (NO), which accounts for the biological activity of the endothelium-derived relaxing factor (EDRF) (for review, see References 1 through 31 2 3 ). NO is produced by oxidation of the terminal guanidino nitrogen of L-arginine by an enzyme, the NO synthase (for review, see Reference 33 ). The development of guanidino-modified arginine analogues as specific inhibitors of NO synthase allowed the study of the effects of basal NO release on the resting tone of resistance vessels and its involvement in blood pressure regulation.4 Since the first demonstration of a remarkable increase in arterial blood pressure after systemic application of NO synthase inhibitors in the rabbit,4 the possible involvement of NO in the development or maintenance of arterial hypertension has been discussed.
The formation and release of endothelium-derived NO into the coronary circulation has been quantified in isolated perfused hearts from the guinea pig5 and rabbit.6 Basal release of NO may be increased severalfold during infusion of endothelium-dependent vasodilators such as bradykinin, acetylcholine, serotonin, and ATP or as a result of an elevated perfusion flow in response to enhanced shear stress.7 In hypertensive patients with and without left ventricular hypertrophy, the coronary flow reserve, determined by endothelium-dependent and -independent vasodilators, is frequently impaired.8 9 10 So far, no experimental or clinical study has been published that quantifies cardiac NO release directly. Thus, a possible pathophysiological role of NO in the regulation of coronary vessel tone in arterial hypertension remains unclear.
Coronary vascular resistance (CVR) of hearts from spontaneously hypertensive rats (SHR), a model for genetically determined hypertension, is significantly higher than that of hearts from the normotensive Wistar-Kyoto (WKY) control strain. Whether or not an altered NO metabolism may account for this difference is unknown. A smaller NO production could potentially explain the higher coronary resistance. Alternatively, at comparable production rates, a faster inactivation of NO, eg, by reaction with superoxide anions,11 could lead to a higher coronary resistance and/or a lower sensitivity of vascular smooth muscles to NO.12
The aim of the present study was to investigate the role of NO in the control of CVR in hypertensive hearts. Using isolated perfused hearts from SHR and WKY rats, we determined (1) the effects of exogenously applied NO on CVR, (2) the release of endogenously produced NO under basal and stimulated conditions, and (3) the effects of NO synthase inhibitors on NO production.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Preparation of Isolated Hearts and Experimental Protocol
SHR and WKY rats (Charles River, Kisslegg, FRG) in the 16th to 22nd week served as an experimental model for genetically determined arterial hypertension (each n=17). Hearts were rapidly excised from diethylether-anesthetized rats according to the guidelines of the local committee for the use of animals in research. Perfusion was performed in a retrograde manner via the aorta at a constant flow rate of 14 mL/min with a modified Krebs-Henseleit solution as described in detail elsewhere.7 With the use of this flow rate, a stable preparation was achieved with hearts from either WKY rats or SHR without changes in the inotropic parameters, left ventricular pressure and dP/dtmax, for up to 2 hours. Moreover, coronary vascular reactivity on bolus infusion of adenosine (20 µL, 100 µmol/L) was similar at the beginning and end of each experiment. Indomethacin (10 µmol/L) was added to the perfusion medium to prevent production and release of prostacyclin. In experiments in which NO release was determined, the perfusion medium was supplemented with 5 µmol/L oxyhemoglobin (see below). Left ventricular systolic pressure (LVP) and its first derivative, dP/dtmax, were continuously measured with a Millar tip catheter inserted into the left ventricle. Coronary perfusion pressure (CPP) was continuously measured in the perfusion cannula 2 cm above the orifice of the coronary vessels. CVR was calculated as the ratio of CPP and flow. The hemodynamic parameters were sampled on a PD-11 computer and documented on a Watanabe linear recorder. Hearts were used for further study only when initial CPP was higher than 70 mm Hg and the bolus injection of adenosine decreased basal CPP by more than 25%. Rejected hearts amounted to 25% in the SHR and 15% to 20% in the WKY groups. At the end of each experiment, hearts were removed from the perfusion cannula, and wet weight was determined after gentle blotting of the endocardial and epicardial surfaces with a paper towel. All compounds infused to modulate NO release were given through a stainless steel cannula placed into the aortic inflow line in the vicinity of the coronary orifices at a rate of 200 µL/min or less. The experimental protocol was started when LVP, dP/dt, CPP, and heart rate had reached stable baseline values, usually 20 to 30 minutes after artificial perfusion was started.
A concentration-response curve for the dilator effect of intracoronarily infused NO was derived by intracoronary infusion of authentic NO standards. Standards of aqueous NO solution were prepared as previously described.7 13 Briefly, NO was dissolved in argon-degassed purified water, and the concentration of this stock solution was routinely determined by high-performance liquid chromatography (HPLC) via its degradation product nitrite. NO stability in these solutions was regularly checked either using a chemiluminescence technique without reductive preprocessing (CLC 750 TR, ECO Systems) or using the difference-spectrophotometric assay in a stop-flow technique to determine NO content via the molar extinction coefficient for the NO-induced conversion of oxyhemoglobin to methemoglobin, as previously described.14 Thereafter, NO solutions were diluted to the desired concentration under argon and kept in gas-tight syringes. The stability of prepared NO solution was maintained over more than 6 hours. For application of NO, these syringes were mounted in a precision infusion pump (Infors AG) and connected to an HPLC steel cannula, which was placed in the aortic inflow line directly in front of the ostium of the coronary arteries to limit destruction of NO during its transport to the tissue. To stimulate endogenous NO production, we used bradykinin at intracoronary final concentrations of 10-8 to 10-7 mol/L. The stereospecific inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was infused at a final concentration of 10-4 mol/L to block endothelial NO production. Bradykinin, indomethacin, adenosine, bovine hemoglobin, and L-NAME were obtained from Sigma Chemical Co.
NO Measurement
The experimental setup and method used to quantify NO release
into the coronary circulation of isolated hearts has been described in
detail elsewhere.7 15 Briefly, an aliquot (9 mL/min) of
the coronary effluent perfusate dripping from the hearts of either WKY
rats or SHR placed in a water-jacketed chamber was transferred by means
of a roller pump to the flow-through cell of a double-beam
dual-wavelength photometer (Shimadzu UV 3000). The spectrophotometric
quantification of NO is based on the equimolar conversion of
oxyhemoglobin to methemoglobin by NO.15 Continuous
measurement of NO release was achieved by the time-dependent recording
of the absorption difference between the absorption maximum and the
isosbestic point of the difference spectrum of oxyhemoglobin versus
methemoglobin (401 versus 411 nm). Kinetics, sensitivity, specificity,
and linearity of the assay for the quantification of NO release into
the coronary circulation have been described extensively
elsewhere.7
Statistics
Basal CPP of isolated hearts from either WKY rats or SHR
revealed an even distribution using a Gaussian function. Differences
between either SHR and WKY hearts or control and the respective
vasodilator response (changes in CPP and CVR) after application of
authentic NO or bradykinin within each group were evaluated by one-way
ANOVA for repeated measures. To test for significance of differences in
basal NO formation and basal hemodynamic parameters between SHR and WKY
hearts, we applied Student's two-tailed t test for unpaired
data. Two-sided probability values of less than or equal to .05 were
considered significant. The relationship between basal NO formation and
basal coronary vascular tone was evaluated using a linear univariate
regression analysis. Data are given for the regression (b),
correlation (r), and determination
(r2) coefficient (see Fig 7). Data
processing was performed with the SPSS software package (release 5.0.1,
SPSS, Inc). Values are given as the mean±SEM; numbers in parentheses
indicate the number of hearts tested with the respective intervention.
|
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Table 1 gives basal hemodynamic parameters of isolated WKY or SHR hearts perfused with a constant flow of 14 mL/min. Although heart rate was comparable in both groups, LVP, and thus dP/dtmax, was approximately 30% higher in SHR compared with WKY hearts. CPP was significantly higher in the SHR group, resulting in a 32% higher CVR in SHR compared with WKY hearts under resting conditions. The wet heart weight determined at the end of each experiment was significantly higher in SHR, corresponding to a 60% higher ratio of heart weight to body weight in SHR compared with WKY rats.
|
Effect of NO Release on Coronary Hemodynamics
Intracoronarily infused NO dilated coronary resistance vessels in
a concentration-dependent manner (see Fig 1). NO is a
powerful coronary vasodilator, as indicated by the low threshold
concentration of 0.1 nmol/L. Already at a concentration of 0.3 nmol/L,
CPP was significantly decreased compared with control values within
each group. Half-maximal effects were achieved at approximately 1
nmol/L NO. Onset of coronary vasodilation was obtained always within
less than 1.5 seconds after the start of NO infusion (corrected for
transit time of dead space). In both groups, NO did not significantly
affect LVP, dP/dtmax, or heart rate at the concentrations
used. Control values for CPP and CVR were significantly higher in SHR
compared with WKY hearts (see Table 1). The absolute drop in CPP and
CVR was consistently higher in SHR than in WKY hearts. However, when
the concentration-response curves for NO-induced changes in CPP were
normalized to the respective control value for CPP in each group, the
curves were superimposable (see Fig 1), indicating that the sensitivity
to NO of the coronary vascular smooth muscle was identical in both
groups.
|
Bradykinin-Induced NO Release
Bradykinin significantly decreased CPP from control in the WKY and
SHR groups at each concentration (10-8 to
10-7 mol/L). The bradykinin-induced coronary vasodilation,
as estimated from the absolute reduction in CPP, was significantly
larger in SHR than in WKY hearts (-33±4 versus -56±4 mm Hg at
10-8 mol/L, -44±3 versus -60±5 mm Hg at
3x10-8 mol/L, and -46±4 versus -60±7 mm Hg at
10-7 mol/L bradykinin for WKY and SHR hearts,
respectively). However, when the data are expressed as percent changes
from control CPP, results were not significantly different between SHR
and WKY hearts (see Fig 2). Consequently, the decrease
in CVR observed on bradykinin infusion was larger in the SHR compared
with the WKY group, whereas percent changes from control were
comparable in both groups (-51% and -50%, WKY and SHR,
respectively; see Table 2). Moreover, CVR normalized to
heart weight (CVRg) was comparable in both groups.
|
|
In the same hearts, NO release into the coronary circulation was measured during bradykinin infusion. Bradykinin increased NO release from isolated WKY and SHR hearts in a concentration-dependent manner. The maximal rates were similar (161±21 and 169±45 pmol/min, WKY versus SHR, respectively). Although NO release from isolated SHR hearts tended to be higher, differences between groups did not reach statistical significance (see Fig 3A). Since the wet heart weight was approximately 30% higher in SHR compared with WKY hearts, the surface of the coronary endothelium that contributes to the total amount of released NO might be higher. Therefore, data for NO release were normalized to organ wet weight, still revealing comparable values for NO release in both groups (see Fig 3B). At a bradykinin concentration of 10-7 mol/L, NO formation increased by 155±20 and 130±35 pmol/minxg over basal release (WKY and SHR, respectively).
|
To evaluate whether the NO concentrations determined in the coronary circulation were sufficient to account for the bradykinin-induced coronary vasodilation, we compared the concentration-response curves of exogenously applied and endogenously formed NO. As can be seen from Fig 4, the amounts of intracoronarily formed NO after bradykinin infusion were within the vasodilator range of exogenously applied NO and can thus readily explain the observed coronary vasodilation. In addition, the slightly higher degree of coronary vasodilation observed on infusion of exogenous NO in SHR hearts was paralleled by a slightly higher NO concentration achieved with intracoronarily applied bradykinin.
|
Effects of Basal NO Release on CVR
Fig 5 shows data for the basal release of NO into
the coronary circulation observed in WKY and SHR hearts. Basal NO
release was approximately 91% higher in SHR compared with WKY hearts
(P<.05). This difference was smaller after normalization
for heart wet weight (50%) but remained statistically significant (see
Fig 5B). To test for the possible physiological and pathophysiological
importance of an elevated basal NO release in SHR hearts, we performed
a separate set of experiments in which L-NAME, a specific inhibitor of
the NO synthase, was infused intracoronarily. At a final concentration
of 10-4 mol/L, L-NAME significantly increased CPP in both
groups. L-NAME–induced coronary vasoconstriction was significantly
more pronounced in SHR hearts compared with WKY hearts (25±3 versus
12±2 mm Hg). When expressed as percent changes from control,
increases in CPP were still significantly higher in SHR (23±1%) than
in WKY (14±2%) hearts. Consequently, CVR on infusion of L-NAME,
either in absolute values or normalized to heart weight, was
significantly higher in SHR compared with WKY hearts (see Table 3).
|
|
We also investigated the effects of L-NAME on basal NO release. L-NAME reduced the basal NO release in WKY hearts by 119 pmol/min and in SHR hearts by 117 pmol/min (see Fig 6A). Thus, although the absolute amount of reduction in NO release by L-NAME was comparable in both groups, the relative degree of the percent inhibition of NO release from control was significantly higher in WKY compared with SHR hearts (-44% versus -22%, respectively). This relation remained the same after data were normalized to heart wet weight, as depicted in Fig 6B.
|
Fig 7 depicts the relation between CPP and NO release under control conditions for individual WKY and SHR hearts. As described before, the average NO release and average CPP were less in the WKY group. Most importantly, close inverse correlations between both parameters were uncovered within each group. The higher the NO release, the lower the CPP. Comparable results were obtained when CVR and basal NO formation were normalized for heart weight, as can be seen in Fig 7.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The major results of the present study are as follows: (1) Coronary vascular smooth muscle of normotensive and hypertensive rats expressed a similar sensitivity toward exogenously applied NO. (2) Bradykinin-induced changes in NO release were comparable in both groups, and the amount of released NO on stimulation with bradykinin was sufficient to account for the observed coronary vasodilation. (3) The higher level of CVR observed in SHR hearts was associated with a significantly elevated rate of basal NO formation. (4) A close inverse relation exists between CVR and basal NO formation within both groups. Collectively, NO synthesis and release into the coronary circulation from SHR hearts is not specifically impaired but rather preserved and critically determines CVR.
During the development of arterial hypertension, several functional and morphological alterations of the vascular endothelium and smooth muscle cells have been described (for review, see References 1616 and 1717 ). Various experimental and clinical studies designed to estimate the pathophysiological importance of NO for the regulation of vessel tone in arterial hypertension have revealed conflicting results18 19 20 (for review, see Reference 2121 ). Current data in the literature do not allow the conclusion that a reduced NO synthesis is the major cause for an increased vascular resistance in arterial hypertension. Most of these functional studies used inhibitors of NO synthase or acetylcholine stimulation to indirectly assess endothelium-dependent vasomotion rather than quantifying NO directly. This direct quantification of NO, however, is crucial to establish a causal relation between a reduced NO production and the blunted endothelium-dependent vasomotion observed in arterial hypertension. The present study is apparently the first that has quantified NO release into the coronary circulation of hypertensive animals.
Effects of Authentic NO on Coronary Hemodynamics
The degree of maximal coronary vasodilation observed after NO
infusion and the low threshold concentration of approximately 1 nmol/L
demonstrate that NO is a powerful dilator of coronary resistance
vessels. The present data clearly indicate that the responsiveness
of coronary vascular smooth muscle to exogenous NO is similar in hearts
from normotensive and hypertensive rats. Therefore, an uncoupling of
the vascular endothelial and smooth muscle compartment by an impaired
diffusion of NO secondary to an intimal thickening is considered
unlikely to represent one pathomechanism for the endothelial
dysfunction observed in arterial hypertension.12
Superoxide anion radicals, which have been demonstrated to be produced
by vascular endothelial cells, may react rapidly with NO to form
peroxinitrite, which decomposes to vasoinactive nitrate and thus has
been considered as an endothelium-dependent
"constricting factor" counteracting the effect of
EDRF/NO.11 22 23 In the present model of arterial
hypertension, however, this interaction appears not to be important for
the regulation of coronary vessel tone, as the dose-response curves for
the NO-induced drop in CPP were superimposable in both groups.
Effects of Bradykinin on Coronary Hemodynamics and NO Release
In the present study, bradykinin rather than acetylcholine,
serotonin, or histamine was chosen to stimulate endothelial NO release
because bradykinin is the more powerful stimulus for NO synthesis in
the coronary circulation,7 and at the concentrations used,
it exerts its action specifically at the endothelium and not at the
vascular smooth muscle.24 As the perfusion medium was
supplemented with indomethacin, effects of prostacyclin on CPP have
been ruled out. Both the degree of coronary vasodilation elicited by
bradykinin and the extent of NO formation were slightly higher in SHR
compared with WKY hearts. Because of its radical nature, NO is
considered to readily pass cellular membranes. Thus, it appears likely
that the amounts of NO released to either the luminal or abluminal site
of the endothelium are comparable. The present setup does not allow
us to conclude that the portion of NO detected photometrically at the
luminal site matches largely the portion of abluminally released
vasoactive NO. However, we can conclude that in both groups the amount
of endogenously formed NO was at least within the vasodilator effective
range of authentic NO and can thus account for the bradykinin-induced
coronary vasodilation (see Fig 4). At present, no data are
available in the literature on hypertension-associated alterations of
endothelium-dependent NO release after stimulation with
bradykinin in the coronary vasculature. However, Cachofeiro and
Nasjletti25 recently reported that in isolated perfused
kidneys from SHR, WKY rats, and angiotensin II–treated
Sprague-Dawley rats, the vasodilator response to bradykinin
was nearly equal in each group. This finding is in line with the
present data and shows that the degree of bradykinin-induced
vasodilation is independent of the rat strain used. This furthermore
weakens the hypothesis that an impaired NO-dependent vasodilation is
responsible for the higher total vascular resistance in hypertension.
Basal Release of NO
Resting and minimal CVR might be affected differently in the
hypertensive heart. Therefore, we further quantified basal NO release
in SHR and WKY hearts. In this study, heart wet weight in 16- to
20-week-old SHR was approximately 30% higher compared with that of the
normotensive control strain. Thus, an increased extravascular pressure
due to myocardial hypertrophy and/or concomitant interstitial fibrosis
may have contributed to the elevated resting CVR. However, even after
CVR was normalized to heart wet weight, CVRg values were
still significantly higher in SHR. This indicates that other factors
within the coronary vasculature, such as functional changes in
endothelial and vascular smooth muscle cells or morphological changes
such as rarefaction of the microvasculature or an increased
wall-to-lumen ratio, must contribute to the increased coronary
resistance.26 Surprisingly, the elevated CVRg
in SHR was accompanied by a 50% increase of NO release into the
coronary circulation. Therefore, the increased resting tone of coronary
vessels cannot be attributed to an impaired NO synthesis. In line with
this interpretation are recently reported data from Arnal et
al27 at the level of the conduit arteries. In that study,
the cyclic GMP content in the aortic wall, as a second messenger of NO,
was not significantly different under control conditions and after
administration of L-NAME between WKY rats and SHR. The authors
concluded that basal release of NO does not appear to be impaired in
SHR, at least in conduit arteries, but represents a major
counterregulatory mechanism for the increased vascular resistance in
this genetic model of arterial hypertension.27 Similar
observations were reported in a very recent study28 in
which basal NO synthase activity, determined by conversion of
radiolabeled L-arginine to L-citrulline, in
aortic segments from SHR was twice that of segments from the
normotensive control strain, probably as a compensatory mechanism to
hypertension at least at the level of conduit arteries.
Rising perfusion flow and shear stress are regarded as major stimuli for the release of basal EDRF/NO.29 30 The experimental setup used in the present study does not allow the measurement of shear stress within the coronary circulation. Because of differences in heart weight, the constant flow perfusion with 14 mL/min resulted in flow rates of 13.5 and 10.8 mL/minxg in WKY and SHR hearts, respectively. It thus appears reasonable that shear stress elicited by saline perfusion medium was higher in the coronary circulation of isolated WKY hearts than in SHR hearts. However, the major determinant of shear stress acting on the luminal site of the endothelium is the vascular tone and thus the height of CVR. Therefore, the elevated CVR, which was more than 30% higher in SHR compared with WKY hearts, may explain the enhanced basal NO formation observed in SHR hearts and may serve the purpose of compensating for increased CVR.
Because of the limited oxygen transport capacity of saline perfusion medium compared with blood, the chosen flow rate is almost 10-fold higher than the prevailing basal coronary blood flow in vivo. This in turn may have resulted in a severalfold higher shear stress at the coronary endothelium in both groups and thus may have contributed in part to the rather high level of basal NO formation compared with the relatively small additional increase in NO formation seen on stimulation with bradykinin. However, the comparison of the sensitivity of coronary vascular smooth muscle with authentic NO and endogenously formed NO on infusion of bradykinin (see Fig 4) will not have been affected by this inherent methodological feature of isolated, saline-perfused hearts, as the rate of basal NO formation was comparable in both experimental groups because of similar perfusion conditions.
The maintenance of flow despite changes in pressure during constant myocardial oxygen demand is considered as autoregulation of coronary blood flow.31 In the canine and human coronary vasculature of hypertrophied ventricles due to arterial hypertension, it has been demonstrated that the lower and upper limits of the autoregulatory range are shifted to higher values.32 33 To test whether the relation between CPP and NO production is changed in SHR, we plotted CPP and CVRg versus NO release (Fig 7). Two interesting features were revealed: (1) Within each group, resting CPP and CVRg increased with decreasing basal NO release, indicating that NO participates in setting the resting tone of resistance vessels of normotensive and hypertensive rat hearts. (2) The relation of CPP and NO release is shifted to higher levels in SHR compared with WKY hearts. This suggests that the increased rate of NO release in SHR hearts helps to maintain CPP closer to physiological levels.
In the present experimental model, the basal NO formation within the coronary circulation significantly determines the resting tone of coronary resistance vessels, as indicated by the coronary vasoconstriction observed on application of L-NAME. Interestingly, L-NAME reduced basal NO release equally effectively in both groups by almost 120 pmol/min, irrespective of the level of basal NO formation, although CPP and CVRg increased more in SHR compared with WKY hearts. This might indicate that not the absolute level of basal NO formation per se but the relation between CPP and NO release is the critical factor in determining the degree of coronary vasoconstriction. Since L-arginine is present in mammalian cells at concentrations of approximately 0.1 to 1 mmol/L, the L-NAME concentrations used may not have been sufficiently high enough to ensure effective competitive blockade of NO synthase. Unfortunately, L-NAME in concentrations higher than 10-4 mol/L interferes with the hemoglobin assay because of its absorbance characteristics, precluding an investigation of its effects on NO formation at higher concentrations. The present data indicate that the hemodynamic response to an inhibitor of NO synthase does not allow one to derive conclusions about the extent of reduction of basal NO release in blood vessels from hypertensive rats or patients without parallel quantification of NO formation. Therefore, the simultaneous determination of NO release and hemodynamic responses appears to be mandatory, and efforts should be directed toward the measurement of this important vasodilator under in situ conditions.
Study Limitations and Future Directions
Although the SHR and its normotensive WKY control strain
represent a widely accepted experimental model for genetically
determined arterial hypertension, species differences in NO release
compared with other models—such as deoxycorticosterone acetate
hypertensive rats; one-kidney, one clip rats; and renin-, angiotensin-,
or coarctation-induced hypertension—cannot be ruled out by the
present study. Thus, data derived from experiments with any of
these animal models of arterial hypertension should be extrapolated to
hypertensive patients only with great caution. Nevertheless, the main
result of the present study shows clearly that increased vascular
resistance is not necessarily linked to decreased NO formation. On the
contrary, basal NO formation rather can be enhanced, at least in the
coronary circulation of SHR, probably as a result of increased shear
stress caused by elevated CVR. However, the results from the
present study do not allow one to decide whether or not the
elevated basal release of NO actually represents a compensatory
reflex mechanism that may help to compensate for the elevated CVR in
hypertensive hearts during the course of hypertension development. To
address this question, long-term studies in 10- to 60-week-old SHR and
WKY rats are highly desirable.
The present study emphasizes the fact that a method for NO quantification under in vivo conditions appears not only desirable but mandatory to assess the pathophysiological significance of NO in arterial hypertension in humans. Because of the extremely rapid metabolism of NO, which is converted to nitrite in human plasma and consecutively oxidized to nitrate within the erythrocytes,34 this aim remains presently unresolved. The oxyhemoglobin assay used in the present study offers the advantage of an on-line detection system for picomolar amounts of NO at its site of release in intact saline-perfused organ preparations. In the future, quantification of NO in vivo via parallel detection of electrochemical activity35 and nitrite34 or nitrosothiols36 as specific indicators of the constitutive NO synthase might represent a promising strategy to resolve this issue.
|
Acknowledgments |
|---|
This work was supported by a grant from the land Nordrhein-Westfalia, Benningsen-Förder-award and by a grant from the Deutsche Forschungsgemeinschaft (SFB 242, A9). We wish to thank Ulrike von der Bey for expert technical assistance and Karin Boden for help in preparing the manuscript.
Received June 7, 1994; first decision August 10, 1994; accepted October 12, 1994.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;53:557-573.
2.
Ignarro LJ. Biological actions and properties of
endothelium-derived nitric oxide formed and released
from artery and vein. Circ Res. 1989;65:1-21.
3. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: biology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142. [Medline] [Order article via Infotrieve]
4.
Rees DD, Palmer RMJ, Moncada S. Role of the
endothelium-derived nitric oxide in the regulation of
blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375-3378.
5. Kelm M, Schrader J. Nitric oxide release from the isolated guinea pig heart. Eur J Pharmacol. 1988;155:317-321. [Medline] [Order article via Infotrieve]
6. Amezcua JL, Dusting GJ, Palmer RMJ, Moncada S. Acetylcholine induces vasodilation in the rabbit isolated heart through the release of nitric oxide. Eur J Pharmacol. 1988;95:830-834.
7.
Kelm M, Schrader J. Control of coronary vascular tone by
nitric oxide. Circ Res. 1990;66:1561-1575.
8. Brush JE, Cannon RO III, Schenke WH, Bonow RO, Leon ML, Maron BJ, Epstein SE. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319:1302-1307. [Abstract]
9.
Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwich GH,
Selwyn AP, Ganz P, Alexander RW. Hypertension and left ventricular
hypertrophy are associated with impaired
endothelium-mediated relaxation in human coronary
resistance vessels. Circulation. 1993;87:86-93.
10. Motz W, Vogt M, Rabenau O, Scheler S, Lückhoff A, Strauer BE. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol. 1991;68:996-1003. [Medline] [Order article via Infotrieve]
11.
Kakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M.
Does superoxide underlie the pathogenesis of hypertension? Proc
Natl Acad Sci U S A. 1991;88:10045-10048.
12. Keitoku M, Okayama H, Satoh Y, Maruyama Y, Takishima T. Does diffuse intimal thickening in human coronary artery act as a diffusion barrier to endothelium derived relaxing factor? Tohoku J Exp Med. 1988;154:413-414. [Medline] [Order article via Infotrieve]
13. Feelisch M. The biochemical pathways of nitric oxide formation from microvasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol. 1991;17(suppl 3):25-33.
14. Kelm M, Feelisch M, Spahr R, Piper HM, Noack E, Schrader J. Quantitative and kinetic characterisation of nitric oxide and EDRF released from cultured endothelial cells. Biochem Biophys Res Commun. 1988;154:236-244. [Medline] [Order article via Infotrieve]
15. Feelisch M, Noack E. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol. 1987;139:19-30. [Medline] [Order article via Infotrieve]
16. Mulvany MJ. Abnormalities of resistance vessel structure in essential hypertension: are these important? Clin Exp Pharmacol Physiol. 1991;18:13-20. [Medline] [Order article via Infotrieve]
17. Dzau VJ, Gibbons GH. Cell biology of vascular hypertrophy in systemic hypertension. Am J Cardiol. 1988;62:30G-35G. [Medline] [Order article via Infotrieve]
18.
Boegehold MA. Reduced influence of nitric oxide on arteriolar
tone in hypertensive Dahl rats. Hypertension. 1992;19:290-295.
19.
Nakamura T, Prewitt RL. Effect of
NG-monomethyl-L-arginine
on endothelium-dependent relaxation in arterioles of
one-kidney, one clip hypertensive rats. Hypertension. 1991;17:875-880.
20. Fozard JR, Part ML. Haemodynamic response to NG-monomethyl-L-arginine in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Br J Pharmacol. 1991;102:823-826. [Medline] [Order article via Infotrieve]
21. Angus JA, Lew MJ. Interpretation of the acetylcholine test of endothelial dysfunction in hypertension. J Hypertens. 1992;10(suppl 7):179-186.
22.
Rosen GM, Freeman BA. Detection of superoxide generated by
endothelial cells. Proc Natl Acad Sci U S A. 1984;81:7269-7273.
23.
Katusic ZS, Vanhoutte PM. Superoxide anion is an
endothelium-derived contracting factor. Am J
Physiol. 1989;257:H33-H37.
24.
Pelc LR, Gross GJ, Warltier DC. Mechanism of coronary
vasodilation produced by bradykinin. Circulation. 1991;83:2048-2056.
25.
Cachofeiro V, Nasjletti A. Increased vascular responsiveness
to bradykinin in kidneys of spontaneously hypertensive rats.
Hypertension. 1991;18:683-688.
26. Strauer BE. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol. 1990;15:775-783. [Abstract]
27. Arnal J-F, Battle T, Ménard J, Michel J-B. The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat. J Hypertens. 1993;11:945-950. [Medline] [Order article via Infotrieve]
28. Nava E, Lüscher TF. Evidence for an increased production of nitric oxide in spontaneously hypertensive rats. Eur J Clin Invest. 1994;24(suppl 2):A254. Abstract.
29.
Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of
endothelium in the vasodilator response to increased flow in vivo.
Hypertension. 1986;8:37-44.
30.
Kelm M, Feelisch M, Deussen A, Strauer BE, Schrader J. Release
of endothelium-derived nitric oxide in relation to
pressure and flow. Cardiovasc Res. 1991;25:831-836.
31. Hoffmann JIE. Transmural myocardial perfusion. Proc Cardiovasc Dis. 1987;24:429-464.
32.
Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML.
The effect of hypertension and left ventricular hypertrophy on the
lower range of coronary autoregulation. Circulation. 1988;77:1108-1115.
33.
Polese A, De Cesare N, Montorsi P, Fabbiocchi F, Guazzi M,
Loaldi A, Guzzi MD. Upward shift of the lower range of coronary flow
autoregulation in hypertensive patients with hypertrophy of the left
ventricle. Circulation. 1991;83:845-853.
34. Kelm M, Feelisch M, Grube R, Motz W, Strauer BE. Metabolism of endothelium-derived nitric oxide in human blood. In: Moncada S, Marletta MA, Hibbs JB Jr, Higgs EA, eds. Biology of Nitric Oxide. Colchester, UK: Portland Press Ltd; 1992:319-322.
35. Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992;358:676-677. [Medline] [Order article via Infotrieve]
36.
Stamler JS, Jaraki O, Osborne J, Mullins ME, Jaraki O, Michel
T, Singel DJ, Loscalzo J. Nitric oxide circulates in mammalian plasma
primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad
Sci U S A. 1992;89:7674-7677.
This article has been cited by other articles:
 |
|
 |
|
  X. Zhou, H. G. Bohlen, S. J. Miller, and J. L. Unthank NAD(P)H oxidase-derived peroxide mediates elevated basal and impaired flow-induced NO production in SHR mesenteric arteries in vivo Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1008 - H1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Shipley and J. M. Muller-Delp Aging decreases vasoconstrictor responses of coronary resistance arterioles through endothelium-dependent mechanisms Cardiovasc Res, May 1, 2005; 66(2): 374 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Su, Q. Zhang, J. Moalem, J. Tse, P. M. Scholz, and H. R. Weiss Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1367 - H1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kreutzer and T. Jue Role of myoglobin as a scavenger of cellular NO in myocardium Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H985 - H991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kelm Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H1 - H5. [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Lee, T.-H. Hwang, G. T. Oh, S. U. Kwon, Y.-H. Choi, and J.-E. Park Genetic factors associated with endothelial dysfunction affect the early onset of coronary artery disease in Korean males Vascular Medicine, May 1, 2001; 6(2): 103 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Barton, L. V. d'Uscio, Y. Hirata, M. Kakoki, H. Hayakawa, A. Tojo, D. Nagata, E. Suzuki, K. Kimura, A. Goto, et al. Hypertension, Diabetes Mellitus, Hypercholesterolemia, and Endothelin B Receptor-Mediated Renal Nitric Oxide Release Response Circulation, June 13, 2000; 101 (23): e228 - e229. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Liao, T. W. Hein, M. W. Vaughn, K.-T. Huang, and L. Kuo Intravascular flow decreases erythrocyte consumption of nitric oxide PNAS, July 20, 1999; 96(15): 8757 - 8761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Qiu, D. Henrion, J. Benessiano, C. Heymes, B. Tournier, and B. I. Levy Decreased Flow-Induced Dilation and Increased Production of cGMP in Spontaneously Hypertensive Rats Hypertension, December 1, 1998; 32(6): 1098 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Radaelli, L. Mircoli, I. Mori, G. Mancia, and A. U. Ferrari Nitric Oxide–Dependent Vasodilation in Young Spontaneously Hypertensive Rats Hypertension, October 1, 1998; 32(4): 735 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bauersachs, A. Bouloumie, A. Mulsch, G. Wiemer, I. Fleming, and R. Busse Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production Cardiovasc Res, March 1, 1998; 37(3): 772 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kelm, S. Schafer, R. Dahmann, B. Dolu, S. Perings, U. K.M Decking, J. Schrader, and B. E Strauer Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation Cardiovasc Res, November 1, 1997; 36(2): 184 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bouloumie, J. Bauersachs, W. Linz, B. A. Scholkens, G. Wiemer, I. Fleming, and R. Busse Endothelial Dysfunction Coincides With an Enhanced Nitric Oxide Synthase Expression and Superoxide Anion Production Hypertension, October 1, 1997; 30(4): 934 - 941. [Abstract] [Full Text]
|
|
|
|
 |
|
 C D A Goonasekera, V Shah, D D Rees, and M J Dillon Nitric oxide activity in childhood hypertension Arch. Dis. Child., July 1, 1997; 77(1): 11 - 16. [Abstract] [Full Text]
|
|
|
|
|
|
N. Ito, J. Bartunek, K. W. Spitzer, and B. H. Lorell Effects of the Nitric Oxide Donor Sodium Nitroprusside on Intracellular pH and Contraction in Hypertrophied Myocytes Circulation, May 6, 1997; 95(9): 2303 - 2311. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Biol. Chem., April 11, 1997; 272(15): 9922 - 9932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hayakawa and L. Raij The Link Among Nitric Oxide Synthase Activity, Endothelial Function, and Aortic and Ventricular Hypertrophy in Hypertension Hypertension, January 1, 1997; 29(1): 235 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsuoka, S. Itoh, M. Kimoto, K. Kohno, O. Tamai, Y. Wada, H. Yasukawa, G. Iwami, S. Okuda, and T. Imaizumi Asymmetrical Dimethylarginine, an Endogenous Nitric Oxide Synthase Inhibitor, in Experimental Hypertension Hypertension, January 1, 1997; 29(1): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nunez, K. Hosoya, D. Susic, and E. D. Frohlich Enalapril and Losartan Reduced Cardiac Mass and Improved Coronary Hemodynamics in SHR Hypertension, January 1, 1997; 29(1): 519 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kelm, M. Preik, D. J. Hafner, and B. E. Strauer Evidence for a Multifactorial Process Involved in the Impaired Flow Response to Nitric Oxide in Hypertensive Patients With Endothelial Dysfunction Hypertension, March 1, 1996; 27(3): 346 - 353. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||